在肝细胞癌中,TREM2促进形成支持瘤的微环境
Hanrui Guo1,2,3, Meiling Wang1,2,4, Caiya Ni1,2
1Key Laboratory of Xinjiang Endemic and Ethnic Diseases, Shihezi University School of Medicine, Shihezi, Xinjiang, China.
Journal of experimental & clinical cancer research : CR
|January 22, 2025
概括
在骨髓细胞2 (TREM2) 上表达的触发受体通过抑制免疫细胞和促进瘤细胞生长来驱动肝细胞癌 (HCC) 的进展. 准TREM2+巨细胞为HCC提供了一个潜在的治疗策略.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 在骨髓细胞2 (TREM2) 上表达的触发受体在免疫信号传递中至关重要,但其在肝细胞癌 (HCC) 中的作用尚不清楚.
- TREM2是一种在髓状细胞上发现的表面受体,与各种病理有关.
研究的目的:
- 为了研究TREM2在HCC的瘤微环境中的功能.
- 确定TREM2对HCC进展的影响,并确定潜在的治疗点.
主要方法:
- 在野生型和Trem2缺乏的小鼠中试验诱导HCC.
- 使用巨细胞和HCC细胞进行体外研究.
- 对临床HCC样本的分析.
主要成果:
- TREM2 缺乏减少了肝脏瘤负担和改变了CD8+ T细胞透.
- 通过IL-1β分泌,TREM2+巨细胞促进了HCC细胞糖解和PKM2的表达.
- TGF-β1阻断逆转了HCC中的TREM2诱导.
结论:
- TREM2+巨细胞通过抑制CD8+T细胞透和促进瘤细胞糖解来驱动HCC的进展.
- 针对TREM2是一个有希望的治疗策略,用于HCC.
关键词:
CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD9 CD8 CD8 CD8 CD9 CD8 CD8 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 是一个字体的字体的字体是什么意思葡萄糖溶解是什么? 葡萄糖溶解在HCC中,HCC是HCC,HCC是HCC.在PKM2中,PKM2是PKM2.在TREM2中,我们可以使用TREM2.更多相关视频
09:11Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
378
00:06An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
8.8K
相关概念视频
The Tumor Microenvironment
6.5K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.5K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
